Beyond CML, imatinib demonstrated substantial clinical efficacy in gastrointestinal stromal tumors (GIST), which frequently harbor activating mutations in c-KIT or PDGFRA that lead to ligand-independent receptor activation and oncogenic signaling. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.